Follow RSS for latest reports on this topicRenal Cell Carcinoma - Market Research and Reports

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2018 [Report Updated: 16-10-2018]

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2018SummaryCarbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Carbonic anhydrase 9 (CA9/CAIX) is an enzyme en...Read More >>>

Published:
2018-10-16

Published by: Global Markets Direct

Prices Starting From:
$3500

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018 [Report Updated: 10-07-2018]

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018SummaryInterleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IR...Read More >>>

Published:
2018-07-10

Published by: Global Markets Direct

Prices Starting From:
$3500

Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 [Report Updated: 29-06-2018]

Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, “Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enroll...Read More >>>

Published:
2018-06-29

Published by: Global Data

Prices Starting From:
$2500

Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 [Report Updated: 30-04-2018]

Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, “Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 provides an overview of Papillary Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Papillary Renal Cell Carcinoma. Report includes an overview o...Read More >>>

Published:
2018-04-30

Published by: Global Data

Prices Starting From:
$2500

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H1 2018 [Report Updated: 17-04-2018]

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H1 2018SummaryCarbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) pipeline Target constitutes close to 9 molecules....Read More >>>

Published:
2018-04-17

Published by: Global Markets Direct

Prices Starting From:
$3500

Metastatic Renal Cell Carcinoma (mRCC) - Pipeline Insight, 2018 [Report Updated: 14-02-2018]

Metastatic Renal Cell Carcinoma (mRCC) - Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Metastatic Renal Cell Carcinoma (mRCC) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with co...Read More >>>

Published:
2018-02-14

Published by: Delve Insight

Prices Starting From:
$1250

Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14-02-2018]

IntroductionDelveInsight's, “Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 report provides comprehensive insights about marketed and Phase III products for Metastatic Renal Cell Carcinoma (mRCC) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 ...Read More >>>

Published:
2018-02-14

Published by: Delve Insight

Prices Starting From:
$2000

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

DelveInsight's Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027. Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdom)• Japan St...Read More >>>

Published:
2018-02-14

Published by: Delve Insight

Prices Starting From:
$3250

Renal cell carcinoma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

DelveInsight's Renal cell carcinoma - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Renal cell carcinoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027. Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdom)• Japan Study Period: 2016-2027 Renal cell carci...Read More >>>

Published:
2018-02-14

Published by: Delve Insight

Prices Starting From:
$3250

Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

DelveInsight's Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology and market outlook for the 7MM.Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdom)• JapanStudy Period: 2016-2027Metastatic Renal Cell Carcinoma...Read More >>>

Published:
2018-02-14

Published by: Delve Insight

Prices Starting From:
$6250

Renal cell carcinoma - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

DelveInsight's Renal cell carcinoma - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Renal cell carcinoma epidemiology and market outlook for the 7MM.Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdom)• JapanStudy Period: 2016-2027Renal cell carcinoma Understanding and Treatment AlgorithmThe mark...Read More >>>

Published:
2018-02-14

Published by: Delve Insight

Prices Starting From:
$6250

NPS+ Renal Cell Carcinoma (EU5) 2018 [Report Updated: 01-02-2018]

Why are some EU5 RCC brands standing out more than others?There are various options available to EU5 oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?NPS+ RCC (EU5) gives ...Read More >>>

Published:
2018-02-01

Published by: FirstWord Pharma

Prices Starting From:
$2655

NPS+ Renal Cell Carcinoma (US) 2018 [Report Updated: 01-02-2018]

Why are some US RCC brands standing out more than others? There are various options available to US oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?NPS+ RCC (US) gives a ...Read More >>>

Published:
2018-02-01

Published by: FirstWord Pharma

Prices Starting From:
$2655

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H1 2018 [Report Updated: 31-01-2018]

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H1 2018SummaryAccording to the recently published report 'Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H1 2018'; Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 15 molec...Read More >>>

Published:
2018-01-31

Published by: Global Markets Direct

Prices Starting From:
$3500

Renal cell carcinoma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]

DelveInsight “Renal cell carcinoma - Epidemiology Forecast To 2025” provides an overview of the epidemiology trends of Renal cell carcinoma in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Renal cell carcinoma prevalent or incident cases segmented by age, sex and subpopulations. The Report also discuss...Read More >>>

Published:
2017-10-10

Published by: Delve Insight

Prices Starting From:
$2750

Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

DelveInsight’s “Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period underta...Read More >>>

Published:
2017-10-10

Published by: Delve Insight

Prices Starting From:
$5750

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2017 [Report Updated: 10-10-2017]

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2017SummaryCarbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Carbonic anhydrase 9 (CA9/CAIX) is an enzyme en...Read More >>>

Published:
2017-10-10

Published by: Global Markets Direct

Prices Starting From:
$3500

Metastatic Renal Cell Carcinoma (mRCC) - Pipeline Insight, 2017 [Report Updated: 31-07-2017]

DelveInsight’s, “Metastatic Renal Cell Carcinoma (mRCC)-Pipeline Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Metastatic Renal Cell Carcinoma (mRCC). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics ...Read More >>>

Published:
2017-07-31

Published by: Delve Insight

Prices Starting From:
$1250

Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 31-07-2017]

DelveInsight’s “Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Metastatic Renal Cell Carcinoma (mRCC) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the pati...Read More >>>

Published:
2017-07-31

Published by: Delve Insight

Prices Starting From:
$5750

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Insights to 2025 [Report Updated: 31-07-2017]

DelveInsight’s “Metastatic Renal Cell Carcinoma (mRCC) -Epidemiology Forecast, 2025” provides an overview of the epidemiology trends of Metastatic Renal Cell Carcinoma (mRCC) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Metastatic Renal Cell Carcinoma (mRCC). The Report also discusses the prevail...Read More >>>

Published:
2017-07-31

Published by: Delve Insight

Prices Starting From:
$2950

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2017 [Report Updated: 18-07-2017]

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2017SummaryInterleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IR...Read More >>>

Published:
2017-07-18

Published by: Global Markets Direct

Prices Starting From:
$3500

Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 01-07-2017]

DelveInsight’s, Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017” report provides comprehensive insights about marketed and Phase III products for the Metastatic Renal Cell Carcinoma (mRCC). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API ma...Read More >>>

Published:
2017-07-01

Published by: Delve Insight

Prices Starting From:
$2000

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2016

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2016SummaryGlobal Markets Direct’s, ‘Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, ...Read More >>>

Published:
2016-10-26

Published by: Global Markets Direct

Prices Starting From:
$3500

Urinary Tract Cancer Market: By Type (Squamous Cell Carcinoma, Transitional Cell Carcinoma, Others); By Diagnostic Tools (Biopsy, Cystoscopy, Others); By Treatment (Biological Therapy, Surgical Treatment, Others) & By Region-Forecast (2016-2022) [Report Updated: 12-09-2016]

Urinary tract cancer was the ninth most frequently occurring cancer type with a high reoccurrence rate in, according to The World Health Organization. The early symptoms of urinary tract cancer is the presence of blood in the urine, haematuria and the risk of this type of cancer is high among the smokers, those with urinary tract infections, geriatric population, and workers in chemical industries...Read More >>>

Published:
2016-09-12

Published by: Industry ARC

Prices Starting From:
$5250

Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016 provides an overview of Metastatic Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Renal Cell Carcinoma. Report includes an overvi...Read More >>>

Published:
2016-07-29

Published by: Global Data

Prices Starting From:
$2500

Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016 provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enroll...Read More >>>

Published:
2016-07-29

Published by: Global Data

Prices Starting From:
$2500

Papillary Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

Papillary Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Papillary Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016 provides an overview of Papillary Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Papillary Renal Cell Carcinoma. Report includes an overview o...Read More >>>

Published:
2016-07-29

Published by: Global Data

Prices Starting From:
$2500

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023SummaryRenal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, being responsible for approximately 90% of al...Read More >>>

Published:
2016-06-01

Published by: Global Data

Prices Starting From:
$3995

Renal Cell Carcinoma - Global Drugs Market Forecast and Pipeline Analysis to 2021 [Report Updated: 16-05-2016]

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of o...Read More >>>

Published:
2016-05-16

Published by: iGATE Research

Prices Starting From:
$1190

Market Access Impact: Renal Cell Carcinoma (US) [Report Updated: 01-05-2016]

Market barriers boost net share for 6 major RCC treatments in US. Is your brand one of them?We researched 9 renal cell carcinoma (RCC) treatments to see what happens to their share of the US market when oncologists can’t prescribe freely. The result: 6 of those brands actually saw a net gain.Is your brand one of them, or one of the 3 that are losing out?You’ll learn how market barriers affect ...Read More >>>

Published:
2016-05-01

Published by: FirstWord Pharma

Prices Starting From:
$4995

Market Access Impact: Renal Cell Carcinoma (EU5) [Report Updated: 01-05-2016]

Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them?We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when oncologists can’t prescribe freely. The result: 5 of those brands saw a net loss. But 3 of them made significant net gains. Is your brand one of them?You’ll learn how market barr...Read More >>>

Published:
2016-05-01

Published by: FirstWord Pharma

Prices Starting From:
$4995

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market is currently dominated by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in particular, but it will experience dramatic changes over the forecast period as patents expire and promis...Read More >>>

Published:
2016-04-21

Published by: Global Data

Prices Starting From:
$10995

Medical Affairs Reputations: Renal Cell Carcinoma (US)

IntroductionOpdivo’s medical affairs team working overtime to engage oncologists. Is it paying off?Opdivo’s medical affairs team has been busy. Since late 2015, when the Anti-PD-1 monoclonal antibody got FDA approval for renal cell carcinoma (RCC) treatment, they’ve been one of the most active teams in the US market.Is it paying off?Find out how oncologists rate Opdivo’s team, and how the ...Read More >>>

Published:
2016-04-01

Published by: FirstWord Pharma

Prices Starting From:
$5995

Medical Affairs Reputations: Renal Cell Carcinoma (EU5)

Introduction4 medical affairs teams working hard to engage oncologists. Which one gets top marks? European medical affairs teams for four renal cell carcinoma (RCC) treatments have been working overtime, interacting with 12-58% more oncologists than any other team in the past 6 months.Is all their hard work paying off?Find out how oncologists rate Opdivo’s team, and how the teams for 7 other maj...Read More >>>

Published:
2016-04-01

Published by: FirstWord Pharma

Prices Starting From:
$5995

Interferon Market: By Disease Treated (Hepatitis-B, Hepatitis C, Melanoma, Leukemia (Interferon Alpha), By Multiple Sclerosis (Interferon Beta), Renal Cell Carcinoma, Leukemia (Interferon Gamma)) By Geography-Forecast (2016-2021) [Report Updated: 18-02-2016]

Interferons can be defines and segmented as a class of proteins generated and released by the host cells against the presence of pathogenic microbes like bacteria, viruses, fungi and tumor cells. Interferon proteins belong to a class of glycoproteins namely cytokines and are is generally considered to be the first line of defence against any microbial infections. Due to the ability of interferons ...Read More >>>

Published:
2016-02-18

Published by: Industry ARC

Prices Starting From:
$5250

NPS+ Renal Cell Carcinoma (US)

IntroductionTwo brands lead the RCC treatment market. How does your brand stack up?US oncologists may not be totally satisfied with available renal cell carcinoma (RCC) treatments, but two brands have earned high satisfaction scores and pulled ahead of the rest. Find out which two, and see how your brand measures up./paragraph>FirstView’s NPS+ Renal Cell Carcinoma report compares brand loyalty f...Read More >>>

Published:
2016-02-01

Published by: FirstWord Pharma

Prices Starting From:
$2495

NPS+ Renal Cell Carcinoma (EU5)

IntroductionCompare 8 major RCC brands. Learn which one scores 6 times higher than any other?FirstView’s NPS+ Renal Cell Carcinoma report compares brand loyalty for 8 major RCC treatments—information you can use to improve your brand’s health, and boost your market share. /paragraph>Based on your brand’s net promoter score (NPS), the report shows you how likely doctors are to recommend you...Read More >>>

Published:
2016-02-01

Published by: FirstWord Pharma

Prices Starting From:
$2495

Global Renal Cell Carcinoma Drugs Market 2020

Renal cell carcinoma, also called renal adenocarcinoma, is a disease in which malignant or cancerous cells are found in the lining of tubules in the kidney. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma. Various tests, like ultrasound, urine analysis, intravenous pyelogram, CT scan, MRI ...Read More >>>

Published:
2016-02-01

Published by: RNCOS

Prices Starting From:
$1500

Renal Cell Carcinoma: KOL Insight

IntroductionWill new checkpoint inhibitors revive immunotherapy in RCC?Renal Cell Carcinoma: KOL Insight offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma and the drug discovery community. Gain insights on what leading clinicians think about current treatment options, new therapies, the critical role of clinical research and the factors ...Read More >>>

Published:
2015-02-01

Published by: FirstWord Pharma

Prices Starting From:
$7900

Global Renal Cell Carcinoma Drugs Market Research Report 2012-2024 [Report Updated: 01-01-1970]

The global Renal Cell Carcinoma Drugs market will reach Volume Million USD in 2017 with CAGR xx% 2019-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describ...Read More >>>

Published:

Published by: HeyReport

Prices Starting From:
$1800